Publications
107 results found
Giamas G, Filipovic A, Jacob J, et al., 2010, Identification of novel kinases modulating ER: new therapeutic targets in breast cancer, Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472
Castellano L, Giamas G, Jacob J, et al., 2009, The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, Vol: 106, Pages: 15732-15737, ISSN: 0027-8424
- Author Web Link
- Cite
- Citations: 282
Castellano L, Giamas G, Jacob J, et al., 2009, Genome wide screen of estrogen receptor -\#945; regulated microRNAs reveals a negative autoregulatory feedback loop, CANCER RESEARCH, Vol: 69, ISSN: 0008-5472
Giamas G, Castellano L, Feng Q, et al., 2009, CK1{delta} modulates the transcriptional activity of ER{alpha} via AIB1 in an estrogen-dependent manner and regulates ER{alpha}-AIB1 interactions., Nucleic Acids Res.
Mintz PJ, Habib NA, Jones JL, et al., 2008, The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer, CANCER, Vol: 113, Pages: 1489-1495, ISSN: 0008-543X
- Author Web Link
- Cite
- Citations: 15
Castellano L, Waxman J, Giamas G, et al., 2008, The identification of new tumour suppressor micromas epigenetically silenced in drug resistant cancer cells, 20th Meeting of the European-Association-for-Cancer-Research, Publisher: PERGAMON-ELSEVIER SCIENCE LTD, Pages: 95-95, ISSN: 1359-6349
Apostolopoulos C, Castellano L, Stebbing J, et al., 2008, Bendamustine as a model for the activity of alkylating agents., Future Oncol., Vol: 4, Pages: 323-332
Giamas G, Ali S, Apostolopoulos C, et al., 2008, The identification of new signaling pathways involved in estrogen receptor-alpha (ERα) transcriptional activity, Joint Conference of the 33rd FEBS Congress/11th IUBMB Conference, Publisher: BLACKWELL PUBLISHING, Pages: 137-137, ISSN: 1742-464X
Castellano L, Waxman J, Giamas G, et al., 2008, The identification of new tumour suppressor microRNAs epigenetically silenced in drug resistant cancer cells, Joint Conference of the 33rd FEBS Congress/11th IUBMB Conference, Publisher: BLACKWELL PUBLISHING, Pages: 152-152, ISSN: 1742-464X
Brockschmidt C, Hirner H, Huber N, et al., 2008, Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo., Gut
von Blume J, Knippschild U, Dequiedt F, et al., 2007, Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2., EMBO J, Vol: 26, Pages: 4619-4633
Apostolopoulos C, Giamas G, Stebbing J, 2007, Clinical significance of circulating tumor cells, Biomarkers in Medicine, Vol: 1, Pages: 341-342
Giamas G, Hirner H, Shoshiashvili L, et al., 2007, Phosphorylation of CK1δ:: identification of Ser<SUP>370</SUP> as the major phosphorylation site targeted by PKA <i>in vitro</i> and <i>in vivo</i>, BIOCHEMICAL JOURNAL, Vol: 406, Pages: 389-398, ISSN: 0264-6021
- Author Web Link
- Cite
- Citations: 51
Giamas G, Stebbing J, Vorgias CE, et al., 2007, Protein kinases as targets for cancer treatment., Pharmacogenomics, Vol: 8, Pages: 1005-1016, ISSN: 1744-8042
In various types of malignancies, conventional forms of therapy (surgery, radiation and chemotherapy) are often ineffective, as well as harmful. In the last few years, a convergence of scientific advances has enabled the identification of molecular targets and signaling pathways specific to cancer cells, resulting in therapies with enhanced selectivity and efficacy and reduced toxicity. Compound validation has relied on target validation first, although some of the most successful drugs often have effects outside of their postulated mechanism. Protein kinases represent such molecular targets; considerable research effort has been devoted to the development of targeted drugs that inhibit the action of pathogenic kinases, and clinical studies performed so far have validated the positive effects of kinase inhibitors for cancer treatment. In this review, the specificity, mechanism of action and antitumor activity of several new small-molecule inhibitors of tyrosine and serine/threonine kinases are discussed.
Wolff S, Stoter M, Giamas G, et al., 2006, Casein kinase 1 delta (CK1delta) interacts with the SNARE associated protein snapin., FEBS Lett.
Knippschild U, Wolff S, Giamas G, et al., 2005, The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development., Onkologie, Vol: 28, Pages: 508-514, ISSN: 0378-584X
The members of the casein kinase 1 (CK1) family are highly conserved and are expressed in many eukaryotes ranging from yeast to humans. Mammalian CK1 isoforms (alpha, beta, gamma, delta, epsilon) and their splice variants are involved in diverse cellular processes including membrane trafficking, circadian rhythm, cell cycle progression, chromosome segregation, apoptosis and cellular differentiation. Mutations and deregulation of CK1 expression and activity has been linked to various diseases including neurodegenerative disorders such as Alzheimer's and Parkinson's disease, sleeping disorders and proliferative diseases such as cancer. In this review, we summarize the functions of CK1 and outline the participation of CK1 in signal transduction pathways linked to cancer development.
Giamas G, Henne-Bruns D, Knippschild U, CK1δ activity is influenced by cellular factors, 8th Cancer Research UK Beatson International Cancer Conference. (2005)
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.